Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.32 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117085 | 0.84 | PDE2A (0.36) | EPRS1SMN1; SMN2PDE2AHRH4 | |
| SCHEMBL14482160 | 0.81 | MEN1 (0.35) | L3MBTL1MEN1KMT2AEPRS1PDE2A | |
| SCHEMBL714757 | 0.81 | L3MBTL1 (0.36) | L3MBTL1HSD17B13MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL844461 | 0.79 | MAPT (0.46) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5302 | 0.79 | GPR139 (0.39) | L3MBTL1MEN1KMT2AGPR139PDE2A | |
| SCHEMBL863617 | 0.79 | ALDH1A1 (0.35) | L3MBTL1MEN1KMT2AEPRS1SMN1; SMN2 | |
| SCHEMBL715924 | 0.79 | OPRK1 (0.41) | — | |
| SCHEMBL11068 | 0.78 | GAA (0.41) | MEN1KMT2AGPR139 | |
| SCHEMBL11849 | 0.77 | KMT2A (0.39) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL715873 | 0.77 | HTT (0.40) | L3MBTL1MEN1KMT2AGPR139PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8957090-B2 | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| EP-2499126-B1 | FUSED BICYCLIC PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-8637543-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| EP-2499144-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-17 | — | — | US | disclosed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, CDK3, MAP3K13 | L3MBTL1 2556/4885HSD17B13 3259/4885MEN1 2197/4885 |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | L3MBTL1 2277/4885HSD17B13 2757/4885MEN1 3000/4885 |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | L3MBTL1 3865/4885HSD17B13 4418/4885MEN1 3086/4885 |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | MAP3K13, MAP3K15, MAP3K12 | L3MBTL1 2687/4885HSD17B13 2323/4885MEN1 3445/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | L3MBTL1 4171/4885HSD17B13 2069/4885MEN1 3999/4885 |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | L3MBTL1 2807/4885HSD17B13 3970/4885MEN1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.